RSNA: Siemens Medical CEO Preaches Single-Source Sermon


Author: Neil Versel
CHICAGO—Hospitals increasingly want all their technology—medical innovations as well as health-IT—from a single vendor, says the chief executive of one of the world’s largest medical technology companies.

“It’s important to be able to offer a fully integrated solution,” says Erich Reinhardt, president and CEO of Siemens Medical Solutions (Erlangen, Germany), since tighter integration usually means better performance. “The old approach of best-of-breed will not work in healthcare.”

That’s perhaps not a surprising perspective from a giant vendor such as Siemens, but it also is not a new attitude within the user community, as the pendulum has been on the side of single-source, enterprise-wide solutions for a while now (see “EHR: Best of Breed Losing Ground to Integrated Apps”). What is new is Reinhardt’s expansion of the definition of “integration” to include heavy diagnostic equipment.

Reinhardt came from Siemens global headquarters in Erlangen, Germany, to host a breakfast with healthcare media Tuesday morning at the Radiological Society of North America (RSNA) annual meeting, the largest medical gathering in the world each year, drawing more than 60,000 people from around the globe to the chilly, breezy shores of Lake Michigan.

Here at RSNA, Siemens is focusing on medical devices for the lucrative imaging market, introducing new and updated MRI, CT, and ultrasound machines, though there is a healthy health-IT component.

Not surprisingly, Siemens is touting the fact that its Soarian Clinicals electronic health record (EHR) is among the first six in-patient products to win approval from the Certification Commission for Healthcare Information Technology this month. (See “CCHIT Certifies the First EHRs for Acute Care.”) The company also is selling its open-architecture Syngo platform to integrate imaging modalities into health-IT from multiple vendors.

“Our IT strategy is based on a platform concept,” Reinhardt says. He says that Soarian is different from its competitors because it’s fully Web-native, so the software does not have to be installed on each workstation, and because it comes with an “integrated workflow engine.”

The Siemens Medical boss says the company has automated more than 100 distinct workflows for Soarian users, and notes that one customer, Chester County Hospital (West Chester, Pa.), won an international award for business process management in 2006 on the strength of its Soarian implementation.

Clearly, though, he sees health-IT from a much broader view than just workflow improvement. Patients are said to have an expectation of safe, accurate, effective, and efficient care—all problems that IT is designed to address. “I think that’s drivel,” the outspoken Reinhardt says. What they really want is access to the best diagnostics and therapy, as fast as possible. (He did not address the important issue of who pays for such care.)

“Innovation is important,” Reinhardt says. Advances in technology helps clinicians detect diseases earlier, leading to a higher likelihood of successful treatment and lower costs and, potentially, more specific information on how patients respond to various treatments.

As biotechnology advances and personalized medicine takes hold advance, biomarkers will become central to designing the most effective, least invasive treatments. “This needs IT,” Reinhardt insists. “We try to demonstrate the clinical relevance rather than the technology.”

Want to read more expert articles like this? Click here to subscribe to Digital HealthCare & Productivity.

Click here to log in.

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

thomson reuters image
Biomarkers: An Indispensible Addition to the Drug Development Toolkit
Examining the Potential of Biomarkers
Sponsored by Thomson Reuters

Biomarkers are becoming an essential part of clinical development. In this white paper, Thomson Reuters provides insight from experts in industry and academia, and explores the role of biomarkers as evaluative tools in improving clinical research and the challenges this presents.

Discover the potential of biomarkers to:

  • Improve decision making
  • Accelerate drug development
  • Reduce development costs


BlueArc_Scientific Data
Scientific Data Lifecycle Management: Preparing for Storage in an Uncertain Future
Sponsored by BlueArc

Managing vast and overwhelming streams of gene sequencing data today requires ultra-high performance systems and processes. With continued rapid advancement and improvements in gene sequencing, expect tomorrow’s instruments to output quantities of genomic information that will dwarf current levels. Help your organization maintain data control and prepare for the future of sequencing through this informative paper that discusses:

  • The information technology challenges of gene sequencing
  • “Intelligent” methods for data management and customization
  • System survival tips... Deciding what data to keep or delete
  • New tools to keep scientists ahead of impending data torrents


SAS Managed image
Managed Innovation, Assured Compliance
Developing, executing and managing the transformation, analysis and submission of clinical research data with SAS® Drug Development
Sponsored by SAS
Get better products to market faster. Download this white paper to discover the top ten challenges facing life science executives and how to overcome them. See how SAS Drug Development transforms clinical data into true innovation.


Life Science Webcasts & Podcasts

Presented by Trade Commission of Spain

Spain Biotech: An Engine for Economic Change 

TCS podcastDiscover how Spain is focusing on biotechnology to be an engine for economic change through gradual internationalization, development and technology transfer.

Regional governments are actively investing in public and private biology research and promoting the creation of knowledge-based companies. Spain’s human capital combined with aggressive investment in biotech research and infrastructure has led to the creation of bio-clusters.

Today, there are nearly 700 Spanish companies engaged in biotechnology, with almost 50 percent growth in funding devoted to research. In fact, spending on internal R & D in biotechnology has grown 46 percent and is close to 300 million Euros.

Access the podcast 

 



More Podcasts

Job Openings

saic_logo

MANAGER, SCIENTIFIC COMPUTING & PROGRAMMING
(Bioinformatics Manager)
SAIC-Frederick, Inc has an exciting opportunity for a Manager, Scientific Computing & Programming - Core Genoytyping Facility in Gaithersburg, Maryland.  In this role, you will lead the Bioinformatics & Analysis Group.
Master’s or equivalent required.  PhD preferred. Six years experience in development of scientific programs in high-performance computing environment including five years supporting scientific research in computational chemistry, biology, or genetics, & two years supervisory experience.  View complete job posting & apply: www.saic-frederick.com. Position #146945.

For reprints and/or copyright permission, please contact The YGS Group, 1808 Colonial Village Lane, Lancaster, PA;

(717) 399-1900 ext. 125, or via email to Ashley.Zander@theYGSgroup.com.